tert-Butyl (1-(5-bromopyrimidin-2-yl)cyclobutyl)carbamate

Catalog No.: 
ACJJNV075
CAS No.: 
2135587-15-2
Molecular Formula: 
C13H18BrN3O2
Molecular Weight: 
328.21
tert-Butyl (1-(5-bromopyrimidin-2-yl)cyclobutyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$328.00InquiryInquiry
100mg95%$504.00InquiryInquiry
250mg95%$807.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (1-(5-bromopyrimidin-2-yl)cyclobutyl)carbamate
IUPAC Nametert-butyl (1-(5-bromopyrimidin-2-yl)cyclobutyl)carbamate
MDL No.-
Molecular FormulaC13H18BrN3O2
Molecular Weight328.21
SMILESO=C(OC(C)(C)C)NC1(C2=NC=C(Br)C=N2)CCC1
InChI KeyBGQHNBMHAZESLS-UHFFFAOYSA-N
SynonymCarbamic acid, N-[1-(5-bromo-2-pyrimidinyl)cyclobutyl]-, 1,1-dimethylethyl ester;1-(5-Bromo-2-pyrimidinyl)-N-Boc-cyclobutanamine;tert-butyl N-[1-(5-bromopyrimidin-2-yl)cyclobutyl]carbamate;tert-Butyl (1-(5-bromopyrimidin-2-yl)cyclobutyl)carbamate
CAS No.2135587-15-2

Synthetic Route by SureRoute

1. ACJJNV075 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEHQO530 route compound structure diagram
    ACEHQO5304248-19-5In Stock
  2. Plus
  3. ACYGHX291 route compound structure diagram
    ACYGHX2911515923-39-3In Stock
  4. Then
  5. ACJJNV075 route product structure diagram
    ACJJNV0752135587-15-2
Inquiry

2. ACJJNV075 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJJNV075 route product structure diagram
    ACJJNV0752135587-15-2
Inquiry

3. ACJJNV075 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJJNV075 route product structure diagram
    ACJJNV0752135587-15-2
Inquiry

Comments (0)